Lenalidomide Can Reverse CLL-Induced T Cell Dysfunction by Inhibiting Both CXCL12-Mediated IL-10 Production by CLL B Cells and Y705-STAT3 Phosphorylation in T Cells In Vitro. The gene discussed is CXCL12; the disease is B-cell chronic lymphocytic leukemia.